-
-
-
-
-
-
-
Aytu BioScience (AYTU) Reports Q1 Revenue of $24.2M, Net Loss of $53.1M
-
-
-
-
-
-
-
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
-
-
-
-
-
-
-
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
-
-
-
-
-
-
-
Aytu BioPharma to Present at Upcoming September Investor Conferences
-
-
-
-
-
-
-
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
-
-
-
-
-
-
-
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
-
-
-
-
-
-
-
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

